KMDA
Kamada Ltd
7월 27일 4:00 PM ET (한국 7/28 05:00)
$6.99
-0.07 ▼ -0.99%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$6.99
+0.00 +0.00%
카마다(KMDA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$403M
스몰캡
P/E
20.0
적정 수준
배당수익률
3.58%
52주 위치
17%
저점 +8% · 고점 -25%
애널리스트
적극 매수
B-
Fundamental health
vs. Drug Manufacturers - Specialty & Generic 소형주
수익성 Top 23%
성장 Top 37%
밸류에이션 Top 47%
재무 안정 Top 53%
| Index | - | P/E | 20 | EPS (ttm) | 0.35 | Insider Own | 45.48% | Shs Outstand | 57.7M | Perf Week | -1.41% |
| Market Cap | 0.40B | Forward P/E | 11.4 | EPS next Y | 43.47% | Insider Trans | - | Shs Float | 31.5M | Perf Month | -2.65% |
| Enterprise Value | 0.34B | PEG | 0.42 | EPS next Q | 0.11 | Inst Own | 16.02% | Short Float | 0.42% | Perf Quarter | -15.58% |
| Income | 0.02B | P/S | 2.22 | EPS this Y | 17.24% | Inst Trans | -1.7% | Short Ratio | 2.99 | Perf Half Y | -11.74% |
| Sales | 0.18B | P/B | 1.55 | EPS next 5Y | 26.89% | ROA | 5.37% | Short Interest | 0.13M | Perf YTD | -0.99% |
| Book/sh | 4.5 | P/C | 5.51 | EPS past 3/5Y | - -2.03% | ROE | 7.97% | 52W High | -25.24% ($9.35) | Perf Year | -9.46% |
| Cash/sh | 1.27 | P/FCF | 23.3 | Sales past 3/5Y | 11.74% 6.25% | ROIC | 7.58% | 52W Low | 7.54% ($6.50) | Perf 3Y | 43.83% |
| Dividend Est. | $0.25 (3.58%) | EV/EBITDA | 8.43 | EPS Y/Y TTM | 26.52% | Gross Margin | 41.16% | Volatility(W/M) | 2.26% 1.85% | Perf 5Y | 28.49% |
| Dividend TTM | 0.25 | EV/Sales | 1.88 | Sales Y/Y TTM | 8.64% | Oper. Margin | 13.98% | ATR (14) | 0.18 | Perf 10Y | 76.07% |
| Dividend Ex-Date | 2026/3/23 | Quick Ratio | 1.9 | EPS Q/Q | 3.92% | Profit Margin | 11.21% | RSI (14) | 41.67 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.33 | Sales Q/Q | 2.78% | SMA20 | -2.92% ($7.2) | Beta | 0.88 | Target Price | $13 |
| Payout | 64.45% | Debt/Eq | 0.04 | Earnings | 2026/5/13 | SMA50 | -5.39% ($7.39) | Rel Volume | 0.87 | Prev Close | $7.06 |
| Employees | 462 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | -26.78% -3.17% | SMA200 | -9.28% ($7.71) | Avg Volume(3M) | 0.04M | Price | $6.99 |
| IPO | 2013/5/31 | Option/Short | Yes/Yes | Trades | 550 | Volume | 37,870 | Change | -0.99% |
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.
Kamada Ltd (KMDA) Investment Analysis
What kind of company is Kamada Ltd?
카마다(KMDA) 배당주
Healthcare · Drug Manufacturers - Specialty & Generic
Small-Cap — Low Volume, High Volatility
A global biopharmaceutical company that develops and manufactures plasma-derived specialty immunoglobulin and protein therapies. It maintains a marketed product portfolio targeting rare and serious diseases, and operates numerous plasma collection centers across the United States, establishing a vertically integrated business structure that spans from raw plasma sourcing to finished pharmaceuticals.
Learn more about Kamada Ltd →Market Cap
$0.4B
Approx. KRW 0.6 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank3391
Employees462people
IPO2013/05/31
Current Price$6.99 ≈ 9,576원
Key Events
⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 13일 (수) · 장 시작 전 EPS -26.8% 매출 -3.2%
🎯 Ex-div 2026년 3월 23일 (월)
🔔 Earnings release 2026년 3월 11일 (수) · 장 시작 전 EPS -12.7% 매출 -1.6%
Is it profitable?
Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
14.0%
✓ 우수
Net Margin
Share of revenue left after taxes and interest are paid
11.2%
✓ 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
41.2%
✓ 부진
ROE
Annual return earned on shareholders' equity (15%+ is strong)
8.0%
✓ 우수
ROA
Annual earnings relative to total company assets
5.4%
✓ 우수
ROIC
Return generated per dollar invested in the business
7.6%
✓ 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.04
✓ Very low debt
Current Ratio
Liquid assets available to cover liabilities due within a year
3.33
✓ 양호
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.90
✓ 양호
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$13.00
현재가 대비 +86.0%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
11.40배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
0.42
저평가
💡 PEG < 1 — 성장 대비 저렴
내년 EPS 예상 성장률
+43.5%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+26.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-30.9%
평균 서프라이즈
2026.05.13
하회
실적 $0.07 · 예상 $0.12 -39.1%
2026.03.11
하회
실적 $0.06 · 예상 $0.08 -22.6%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Strong Growth
Above the industry average, both historically and going forward
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+17.2%
양호
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+43.5%
우수
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+26.9%
우수
📊 How much has it grown? (actual results)
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-2.0%
평균
Past 5-Year Revenue
How much revenue grew over the past 5 years
+6.3%
평균
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+2.8%
양호
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Long-term weakness — -40%p below the market
KMDA +28.5% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-39.9%p
Significantly behind the market
vs Health Care (XLV)
+4.0%p
roughly in line with the sector average
1-year basis
vs S&P 500
-25.5%p
behind the market
vs Health Care (XLV)
-29.2%p
behind the sector average
Rank among peers
5-year return Upper-Mid (28%) Based on 25 peers
1-year return Lower-Mid (lower 44%) Based on 28 peers
Current position within 52-week range
Low (-7.5%p) High (-25.2%p)
Current price is 7.5% above the 52-week low and 25.2% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-25.8%
Annualized volatility
32.1%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-27
Downtrend zone
Current price $6.99 below the midline ($7.20). Normal downward flow. Below the Ichimoku cloud (bearish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-27
Bearish momentum holding
MACD -0.114 < Signal -0.111 in negative zone + Hist negative (-0.003). Weakness in progress.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-27
Bearish zone
RSI 41.6 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 22.2.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
In line with the industry average
Cheap on Vs. Earnings·Vs. Assets·Vs. Cash Flow, In line with peers on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Earnings Cheap
Vs. Assets Cheap
Vs. Sales Mid-range
Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
20.00x
✓ Cheap
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
11.40x
✓ Fair
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.55x
✓ Cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
2.22x
✓ Fair
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
8.43x
✓ Cheap
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
23.30x
✓ Fair
Analyst target price (reference)
$13.00 vs. current price +86.0%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic
Who owns it?
Ownership flow shows some pressure
Institutional net selling -1.7% · Short interest light 0.4%
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-1.7%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 16.0%
Retail-led
🧑💼 Insiders 45.5%
Founder/management large holders (strong skin-in-the-game)
👤 Retail investors (estimated) 38.5%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
0.4%
Low — limited short-side pressure
Past 90 days Little change
Short interest days to cover
3.0 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 57.7M주
Float (tradable shares) 31.5M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding KMDA
ETFs with the highest weightings · 10 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
배당주 — 연 3.58% 배당
Dividend Yield
3.58%
Industry average 1.23%
Dividend Per Share
$0.25
Annualized
Payout Ratio
64%
Share of net income paid as dividends
5-Year Growth
-
Annualized dividend growth
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$0.01
2013
$0.20 +3233.3%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 3건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2026-03-23
$0.250
—
3.05%
2025-03-17
$0.200
—
2.94%
2013-06-13
$0.006
—
0.06%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 3.0만원
5년 누적 (세후) 15.2만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| KMDA This Stock | $403.3M | 20.0 ▲ | 1.6 ▲ | 7.97% ▲ | 3.58% ▲ | -1.0% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 카마다(KMDA)?
카마다(KMDA) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of KMDA?
The market cap of KMDA is approximately $403M, ranking 3,391 within its sector.
Does KMDA pay dividends?
KMDA has a dividend yield of approximately 3.58%, with an annual dividend of $0.25.
What is the P/E ratio of KMDA?
KMDA has a P/E ratio of approximately 20.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for KMDA?
KMDA has recorded a 52-week high of $9.35 and a low of $6.50.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.